GLP‑1 Market Expands

Glucagon-like peptide 1 drugs started as weekly weight-loss shots, but by April 2026 the market had expanded into a two-pill race led by Novo Nordisk and Eli Lilly. (fda.gov) These medicines mimic a gut hormone that helps people feel full and eat less. The newer shift is not the biology but the format: daily tablets are now joining injectables that dominated the category in 2023, 2024 and 2025. (nejm.org) Novo Nordisk won the first United States approval for an oral obesity version of semaglutide in December 2025 and said it expected a United States launch in early January 2026. That made Wegovy the first daily oral glucagon-like peptide 1 drug cleared for chronic weight management. (nejm.org; ntb.no) Eli Lilly followed on April 1, 2026, when the Food and Drug Administration approved Foundayo, the brand name for orforglipron, for adults with obesity or overweight plus weight-related medical problems. Lilly began shipping it through LillyDirect on April 6 and said on April 9 that retail pharmacies nationwide were getting supply. (fda.gov; prnewswire.com) The two pills do not work exactly the same way for patients using them. Lilly said Foundayo can be taken any time of day without food or water restrictions, while oral Wegovy still carries the empty-stomach routine long associated with semaglutide tablets. (prnewswire.com; usnews.com) Trial results also show why neither company is treating pills as a simple replacement for shots. In the OASIS 4 study published in September 2025, adults taking oral semaglutide 25 milligrams lost 13.6% of body weight on average at 64 weeks, versus 2.2% on placebo. (nejm.org; cbsnews.com) In Lilly’s ATTAIN-1 study, adults without type 2 diabetes lost 7.5% to 11.2% of body weight at 72 weeks, depending on dose, versus 2.1% on placebo. Lilly’s medical information site says that was enough for approval, but still leaves Zepbound, its injectable obesity drug, in the company’s lineup rather than on the chopping block. (medical.lilly.com) The market case for pills is access as much as efficacy. CNBC reported on April 7 that doctors were seeing new patients come in for Novo’s pill who had delayed treatment because of needle fear or out-of-pocket costs tied to injections. (cnbc.com) Price is part of that push. Lilly said Foundayo starts at $25 a month for some commercially insured patients and $149 a month for the lowest self-pay dose through LillyDirect, a lower entry point than many branded injectable regimens. (prnewswire.com) Analysts are already modeling pills as a growth driver for the whole category, not just a swap within it. JPMorgan wrote that 2026 market growth should be helped by lower prices, broader Medicare access and approvals for oral glucagon-like peptide 1 drugs. (jpmorgan.com) That leaves the obesity business looking less like a single blockbuster shot and more like a menu: weekly injections for some patients, daily pills for others, and companies trying to keep both on hand as the field gets bigger. (cnbc.com; jpmorgan.com)